Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Panitumumab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cabozantinib and Panitumumab | EXPERIMENTAL | 60 mg Cabozantinib PO daily and 6 mg/kg Panitumumab IV every 2 weeks. |
| Cabozantinib | EXPERIMENTAL | 60 mg Cabozantinib PO daily. |
| Name | Type | Description |
|---|---|---|
| Panitumumab | BIOLOGICAL | The FDA approved dose for panitumumab is 6mg/kg IV, every two weeks. This is the dose and schedule that will be used in this study. |
| Cabozantinib | DRUG | There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort. Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily. |
MET Amplification Screening Test Inclusion Criteria: 1. Histologically and/or cytologically confirmed and radiographically measurable KRAS wild-type adenocarcinoma of the colon or rectum that is metastatic and/ or unresectable. Subjects must have been treated with a fluoropyrimidine (e.g., 5-fluoro...
Top 20 of 77 competitors
Panitumumab is a monoclonal antibody being studied for the treatment of colorectal cancer. It is currently in Phase 1 clinical development as an investigational therapy. In a completed Phase 1 trial, it was evaluated in combination with cabozantinib for patients with KRAS wild-type metastatic colorectal cancer.
Panitumumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). By binding to EGFR, it is designed to interfere with cancer cell growth and survival pathways. This mechanism is relevant in colorectal cancer, particularly in tumors that are KRAS wild-type, where EGFR signaling plays a role in disease progression.
Panitumumab is being developed by Exelixis, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol EXEL. The company is conducting clinical research to evaluate the drug's safety and efficacy in colorectal cancer, with the most recent trial being a Phase 1 study.
Panitumumab is in Phase 1 clinical development for colorectal cancer. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial, which has been completed, enrolled 29 participants and was designed to assess the combination of panitumumab with cabozantinib in metastatic colorectal cancer.
Panitumumab has been studied in one clinical trial, identified as NCT02008383, titled 'Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer.' This Phase 1 trial was completed and enrolled 29 participants in the United States. The study was controlled but not randomized or double-blinded, and it included biomarker-selected patients.
Panitumumab is the same drug as Vectibix, which is a brand name for panitumumab. In clinical trials, it is referred to by its generic name, panitumumab. The drug is being investigated for use in colorectal cancer, particularly in patients with KRAS wild-type tumors, as part of a combination therapy approach.